Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Council Conditionally Approves 1st Technology for Use Under Patient-Initiated Mixed Care at Univ. of Tokyo Hospital
September 26, 2016
- Pharma, Govt Hold 1st Kanmin Taiwa Working Group Talks; Industry Calls for Trial-Friendly Environment, Discussions on Pricing
September 23, 2016
- Panel Backs Approval of Add’l Indication for J-TEC’s Cell Sheet JACE
September 21, 2016
- Combo Use of 2 Different Hep B Vaccines Produced Necessary Antibody Titer, No Serious ADRs: Report
September 21, 2016
- AMED Official Outlines Pre-Orphan Designation Support Scheme
September 20, 2016
- 3 Major Regulators Will Cooperate on Common Guidelines for Development of Antibacterial Drugs: PMDA Official
September 20, 2016
- As Personal Info Law Amendment Looms, Govt Official Tells Drug Makers to Review Info in Hand
September 16, 2016
- International Meeting of World Pharmacopoeias OKs GPhP Draft
September 16, 2016
- In-Kind Research Support Would Be Effective in Commercializing Drug Seeds: Paper
September 15, 2016
- FY2015 Japan Drug Spending Up 11% on Hep C Meds
September 15, 2016
- Industry Chiefs, Chuikyo Panelists Trade Barbs over Market Expansion on Add’l Indications
September 15, 2016
- 3 Pharma Groups Firmly Oppose Out-of-Cycle Re-Pricing at Chuikyo
September 15, 2016
- G-CSF Preparations Ordered to Add Anaphylaxis in ADR List
September 14, 2016
- Blue Book “Will Be Used as Reference When Selecting Generics”: Panel Chair
September 14, 2016
- PMDA, FDA, EMA Agree on 6 Regulatory Approaches on AMR
September 13, 2016
- G7 Health Ministers Adopt Kobe Communique
September 13, 2016
- Generics from 5 Companies Enough When Major Products Lose Patent Protection: Top Bureaucrat
September 13, 2016
- Kaketsuken “Should Seriously Reflect” on Its Conduct before Asking for Permission to Continue Business: Health Minister
September 12, 2016
- MHLW Panel Backs Approval of Pembrolizumab, Some Voice Concerns for Its High NHI Price
September 12, 2016
- MHLW Panel OKs Humira for Uveitis
September 12, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…